Ralf Trappe

Head of department

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ralf Trappe is the Head of Department at Ev. Diakonie-Krankenhaus Bremen, Germany. His research primarily focuses on post-transplant lymphoproliferative disorders, chronic lymphocytic leukemia, and innovative immunotherapy approaches. He has contributed to numerous studies aimed at improving patient outcomes through tailored treatment strategies and consensus guidelines in oncology.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Dita Gratzinger

Stanford University School of Medicine

UNITED STATES

View details

Leo Hansmann

GERMANY

View details

Christian P. Pallasch

Professor

University Hospital Düsseldorf

GERMANY

View details

Michael Green

UNITED STATES

View details

Daniel Dulek

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

View details

Upton Allen

CANADA

View details

Vikas Dharnidharka

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ralf Trappe

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The IPTA Nashville Consensus Conference on Post‐Transplant lymphoproliferative disorders after solid organ transplantation in children: III – Consensus guidelines for Epstein‐Barr virus load and other biomarker monitoring

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.

Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV<sup>+</sup> PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib with or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder

Collaborators (7)

Dita Gratzinger

Leo Hansmann

Christian P. Pallasch

Michael Green

Daniel Dulek

Upton Allen

Vikas Dharnidharka

Make your next move.

Ralf Trappe

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The IPTA Nashville Consensus Conference on Post‐Transplant lymphoproliferative disorders after solid organ transplantation in children: III – Consensus guidelines for Epstein‐Barr virus load and other biomarker monitoring

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.

Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV&lt;sup&gt;+&lt;/sup&gt; PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib with or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder

Collaborators (7)

Dita Gratzinger

Leo Hansmann

Christian P. Pallasch

Michael Green

Daniel Dulek

Upton Allen

Vikas Dharnidharka

Make your next move.

Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV<sup>+</sup> PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study